220 related articles for article (PubMed ID: 30463393)
1. Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor.
Zhang C; Zhang H; Huang LS; Zhu S; Xu Y; Zhang XQ; Schooley RT; Yang X; Huang Z; An J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30463393
[TBL] [Abstract][Full Text] [Related]
2. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
3. Rational design of HIV-1 entry inhibitors.
Debnath AK
Methods Mol Biol; 2013; 993():185-204. PubMed ID: 23568472
[TBL] [Abstract][Full Text] [Related]
4. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
Teixeira C; Serradji N; Maurel F; Barbault F
Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
[TBL] [Abstract][Full Text] [Related]
5. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
Durdagi S; Mavromoustakos T; Papadopoulos MG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
Curreli F; Kwon YD; Belov DS; Ramesh RR; Kurkin AV; Altieri A; Kwong PD; Debnath AK
J Med Chem; 2017 Apr; 60(7):3124-3153. PubMed ID: 28266845
[TBL] [Abstract][Full Text] [Related]
7. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M
ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750
[TBL] [Abstract][Full Text] [Related]
8. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
10. CoMFA and CoMSIA studies on HIV-1 attachment inhibitors.
Lu P; Wei X; Zhang R
Eur J Med Chem; 2010 May; 45(5):1792-8. PubMed ID: 20149491
[TBL] [Abstract][Full Text] [Related]
11. Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis.
Moonsamy S; Dash RC; Soliman ME
Molecules; 2014 Apr; 19(4):5243-65. PubMed ID: 24762964
[TBL] [Abstract][Full Text] [Related]
12. Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement.
Tuyishime M; Lawrence R; Cocklin S
Bioorg Med Chem Lett; 2016 Jan; 26(1):228-34. PubMed ID: 26531151
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
14. Kinetic Characterization of Novel HIV-1 Entry Inhibitors: Discovery of a Relationship between Off-Rate and Potency.
Meuser ME; Murphy MB; Rashad AA; Cocklin S
Molecules; 2018 Aug; 23(8):. PubMed ID: 30081466
[TBL] [Abstract][Full Text] [Related]
15. In silico study on indole derivatives as anti HIV-1 agents: a combined docking, molecular dynamics and 3D-QSAR study.
Balupuri A; Gadhe CG; Balasubramanian PK; Kothandan G; Cho SJ
Arch Pharm Res; 2014 Aug; 37(8):1001-15. PubMed ID: 24338530
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
Xu HR; Fu L; Zhan P; Liu XY
SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.
Curreli F; Choudhury S; Pyatkin I; Zagorodnikov VP; Bulay AK; Altieri A; Kwon YD; Kwong PD; Debnath AK
J Med Chem; 2012 May; 55(10):4764-75. PubMed ID: 22524483
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV.
Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
J Biomol Struct Dyn; 2019 Jan; 37(1):131-146. PubMed ID: 29268664
[TBL] [Abstract][Full Text] [Related]
19. Biological profiling of anti-HIV agents and insight into CCR5 antagonist binding using in silico techniques.
Carrieri A; Pérez-Nueno VI; Fano A; Pistone C; Ritchie DW; Teixidó J
ChemMedChem; 2009 Jul; 4(7):1153-63. PubMed ID: 19544518
[TBL] [Abstract][Full Text] [Related]
20. Binding site exploration of CCR5 using in silico methodologies: a 3D-QSAR approach.
Gadhe CG; Kothandan G; Cho SJ
Arch Pharm Res; 2013 Jan; 36(1):6-31. PubMed ID: 23325486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
